A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Study Summary

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

Conditions

Solid Tumor, Adult

Interventions / Drugs

CRB-701 Anti-PD-1

View on ClinicalTrials.gov ↗

Sponsor

CRBP

Corbus Pharmaceuticals

Oncology

D37/100

Study Details

Enrollment348 participants

Primary Completion—

Lead SponsorCorbus Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:10:39.232143+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.